<DOC>
	<DOCNO>NCT02113657</DOCNO>
	<brief_summary>The goal clinical research study study impact ipilimumab immune system patient currently receive hormone therapy . The safety drug combination also study .</brief_summary>
	<brief_title>T-Cell Responses Neoantigens Post Treatment With Ipilimumab Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive ipilimumab vein 90 minute Weeks 1 , 4 , 7 , 10 . Your blood pressure measure every 30 minute infusion , well hour finish receive study drug . You continue receive current hormone therapy schedule . You give standard drug ( steroid ) help decrease severe side effect . You may ask study staff information drug give risk . Study Visits : You study visit dose ipilimumab , every 4 week total 3 visit last dose ipilimumab . At visit , follow test procedure perform : - You physical exam . - Blood ( 3 tablespoon ) urine collect routine test . This blood also use measure protein , PSA level . - Blood ( 7 tablespoon ) urine collect test biomarkers . ( Weeks 7 , 14 , 22 ) - Blood ( 1Â½ teaspoon ) draw check testosterone level . ( Week 10 ) - Blood ( 10 tablespoon ) draw test immune system . You sign separate consent form blood draw . At Weeks 14 22 , follow test procedure perform check status disease : - You may chest x-ray . - You CT scan MRIs abdomen , pelvis . If doctor think need , also CT scan chest . If CT scan chest do , chest x-ray require . - You bone scan . If study doctor think need , may additional bone scan CT scan MRIs abdomen , pelvis , chest check status disease . Length Study : You may receive study drug 10 week . You remain study ( receive standard hormone therapy ) total 22 week . You take study treatment intolerable side effect , disease get bad , unable follow study direction . If develop certain side effect certain side effect long period time , may take study . The study doctor let know need take study . This investigational study . Ipilimumab FDA approve commercially available treatment melanoma . Its use treat prostate cancer investigational . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Signed write Informed Consent protocol . 2 . Agreed participate laboratory protocol PA130291 test biomarkers describe clinical protocol . 3 . Patients include study must &gt; /= 18 year old . 4 . Histologically cytologically confirm carcinoma prostate . 5 . Subjects must metastatic prostate cancer mass tissue collection within 3 month study entry . 6 . Evidence metastatic disease previous bone scan , CT scan and/or MRI . 7 . Asymptomatic minimally symptomatic . 8 . Tumor progression hormone therapy castrate level serum testosterone ( &lt; /= 1.7 nmol/L 50 ng/dL ) define biopsyproven , PSA and/or radiographic criterion accord Prostate Cancer Working Group 2 ( PCWG2 ) .Castrate level testosterone must maintain surgical medical mean throughout conduct study . 9 . ECOG performance status &lt; /= 1 . 10 . Patients must normal organ marrow function define : ) WBC &gt; /= 2500/uL . ; b ) ANC &gt; /= 1000/uL . ; c ) Platelets &gt; /= 75 x 10^3/uL . ; ) Hemoglobin &gt; /= 9 g/dL . ; e ) Creatinine &lt; /= 2.5 x ULN . ; f ) ALT &lt; /= 2.5 x ULN patient without liver metastasis . For patient liver metastasis ALT &lt; /= 5 x ULN allow . ; g ) Bilirubin &lt; /= 2.5 x ULN ( except patient Gilbert 's Syndrome , must total bilirubin &lt; /= 3mg/dL ) . 11 . Patient agree use adequate contraception ( barrier method birth control ) prior study entry , therapy 3 month last dose ipilimumab . 1 . Treatment follow medication intervention concomitantly within 28 day start ipilimumab : . ) Systemic corticosteroid . Use inhale , intranasal , intraarticular topical steroid acceptable , short course ( i.e . &lt; /= 1 day ) corticosteroid prevent reaction IV contrast use CT scan . ; b . ) External beam radiation therapy major surgery require general anesthetic . ; c. ) Any systemic therapy prostate cancer ( exception bisphosphonates RANKligand inhibitor bone metastasis allow ) include chemotherapy , secondary hormonal therapy ( megestrol acetate , diethylstilbestrol , ketoconazole , abiraterone , enzalutamide ) nonsteroidal antiandrogens ( bicalutamide , flutamide nilutamide ) . ; d. ) Immune modulators , cytokine vaccine management cancer noncancerrelated illness . ; 2 . ( Exclusion Criteria # 2 Cont . ) : e. ) Any nononcology vaccine therapy use prevention infectious disease ( one month dose ipilimumab ) . ; f. ) Any investigational product . 3 . Use controlled schedule III control substance cancerrelated pain control . 4 . Autoimmune disease : Patients history inflammatory bowel disease ( include Crohn 's disease ulcerative colitis ) autoimmune disorder rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , Systemic Lupus Erythematosus autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] exclude study . 5 . Any underlying medical psychiatric condition , opinion Investigator , make administration study drug hazardous obscure interpretation AEs , condition associate frequent diarrhea . 6 . Patients know brain metastasis . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , history congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . Known HIV , Hepatitis B , Hepatitis C. 9 . Untreated symptomatic spinal cord compression . 10 . Other malignancy require active therapy know associate altered immune response . 11 . Patients history acute diverticulitis , intraabdominal abscess , GI obstruction abdominal carcinomatosis know risk factor bowel perforation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone therapy treatment</keyword>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>gonadotropin-releasing hormone</keyword>
	<keyword>GnRH</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Yervoy</keyword>
	<keyword>BMS-734016</keyword>
	<keyword>MDX010</keyword>
</DOC>